Zura Bio (id:5535 ZURA)
2.73 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:13:01 AM)
Exchange closed, opens in 1 day 23 hours
-7.46 USD (-7.46%)
-12.22 USD (-12.22%)
-32.59 USD (-32.59%)
-50.63 USD (-50.63%)
-39.60 USD (-39.60%)
-72.00 USD (-72.00%)
About Zura Bio
Market Capitalization 178.25M
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
| Headquarters (address) |
1489 W. Warm Springs Road Henderson 89014 NV United States |
| Phone | 702-757-6133 |
| Website | https://zurabio.com |
| Employees | 14 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ZURA |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.00 - 6.35 |
| Market Capitalization | 178.25M |
| P/E trailing | 7.95 |
| P/E forward | -3.69 |
| Price/Book | 1.16 |
| Beta | 0.135 |
| EPS | -0.390 |
| EPS United States (ID:6, base:3400) | 24.26 |